ZURICH/MUNICH (Reuters) – An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals.
FILE PHOTO: The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel January 30, 2014. REUTERS/Ruben Sprich/File Photo
Trial data released on Saturday shed light on the treatment of triple-negative tumors, which affect 15 percent of breast cancer patients, typically affecting younger-than-average women.
An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.
(Reuters Health) – Hispanics in the U.S. have lower rates of death from heart disease overall than non-Hispanic whites, except in communities where Hispanics make up most of the population, a recent study finds.
Overall, counties with higher Hispanic populations also face more economic disadvantages, a lack of access to quality healthcare, and language barriers, researchers report in the Journal of the American Heart Association.
“I think that these neighborhood-specific factors largely explain the disparity,” said lead study author Dr. Fatima Rodriguez of Stanford University in California in an email.
KINSHASA (Reuters) – The leading Ebola expert at the U.S. Centers for Disease Control and Prevention (CDC) said on Friday he believed an outbreak in Congo can be brought under control quickly and that the high rate of new cases is due largely to improved detection.
The haemorrhagic fever’s outbreak in eastern Democratic Republic of Congo is believed to have killed 144 people since July and infected another 79, and the rate of new cases has accelerated sharply in recent weeks.
Ensuring that people with preexisting health conditions can get and keep health insurance has become one of the leading issues around the country ahead of this fall’s midterm elections. And it has put Republicans in something of a bind — many either voted to repeal these coverage protections as part of the 2017 effort in Congress or have signed onto a lawsuit that would invalidate them.
Meanwhile, the Trump administration, eager to show progress regarding high prescription drug costs — another issue important to voters — has issued a regulation that would require prices to be posted as part of television drug advertisements.
Back in 2004, California’s children’s hospitals asked voters to approve a $750 million bond measure to help fund construction and new medical equipment. In 2008, they asked for $980 million more. Now they’re hoping voters will agree on Nov. 6 to cough up an additional $1.5 billion.
The state’s 13 children’s hospitals treat California’s sickest kids — including those with leukemia, sickle cell disease, rare cancers and cystic fibrosis — so approving their fund-raising requests is an easy “yes” for many voters.
(Reuters Health) – Women with silicone breast implants may have a higher risk of certain medical problems than women who don’t get implants, but more research is needed to get a complete picture of implant safety over the long term, a new U.S. study suggests.
The U.S. Food and Drug Administration (FDA) banned silicone breast implants in 1992 over concerns about an increased risk of cancer, connective tissue diseases and autoimmune disorders that were disproved by subsequent research. As a condition of approving a new generation of silicone implants in 2006, the FDA required manufacturers to gather long-term safety information.
T cells help fight off infection, but they can go overboard. A new study led by researchers at the University of Pennsylvania School of Dental Medicine and the National Institutes of Health (NIH) shows that a subset of T cells contributes to the problematic inflammation and bone loss that is associated with periodontitis, a severe form of gum disease.
The research, conducted with the help of animal models and a group of human patients with a rare genetic mutation, point to a new target for treating periodontitis, as well as other diseases involving the inappropriate response of this group of T cells, known as Th17 cells. These include autoimmune conditions such as rheumatoid arthritis and multiple sclerosis. The work appears in Science Translational Medicine.